Key result
Lercanidipine hydrochloride reduced diastolic blood pressure from 96 to 83 mmHg, with effects similar to felodipine sustained-release.
Why the study?
Does lercanidipine hydrochloride reduce diastolic blood pressure compared to felodipine sustained-release in adult patients with mild-to-moderate primary hypertension?
RCT (n=281)
Open-label
1:1 ratio
Yes
Does lercanidipine hydrochloride reduce diastolic blood pressure compared to felodipine sustained-release in adult patients with mild-to-moderate primary hypertension?
Lercanidipine is as effective and safe as felodipine sustained-release for short-term blood pressure control in mild-to-moderate primary hypertension.
Answers are grounded in this paper and cite their sources.
Supports lercanidipine as equivalent option in mild-to-moderate hypertension; confirms similarity to felodipine in RCT.
OBJECTIVE: Lercanidipine hydrochloride and felodipine sustained-release tablets comparison for the treatment of patients with mild-to-moderate primary hypertension. RESEARCH DESIGN AND METHODS: The study was designed as a multicenter, randomized, open-label, parallel-group clinical trial. A total of 281 adult patients (18-75 years) with a mild-to-moderate primary hypertension diagnosis were randomly assigned, in a 1:1 ratio, to lercanidipine hydrochloride (n = 139; 81 males) or felodipine sustained-release tablets (n = 142; 87 males). Study duration was 8 weeks, including two run-in weeks and 6 weeks of treatment. MAIN OUTCOME MEASURES: The mean seated diastolic blood pressure (BP) change from baseline to 6 weeks of treatment was the primary endpoint. Main secondary efficacy parameters were: (i) mean seated systolic BP change from baseline to 6 weeks of treatment; (ii) normalization BP rate. The incidence of adverse events was also considered. RESULTS: BP monitoring showed a significant decrease compared with baseline in diastolic BP (lercanidipine: from 96 ± 4 to 83 ± 6 mmHg, p < 0.0001; felodipine: from 96 ± 4 to 82 ± 5 mmHg, p < 0.0001). The mean systolic BP decreased, when compared with baseline values, by 18 mmHg and 19 mmHg in the lercanidipine and felodipine arm, respectively (p < 0.0001 versus baseline for both comparisons). The normalization rates of BP were 79.5% and 87.2%, in the lercanidipine and felodipine groups, respectively (in-office monitoring; p = n.s.). In total, 73 patients experienced 103 AEs: 26.6% (37/139) in the lercanidipine group and 25.3% (36/142) in the felodipine arm (p = n.s.). The analysis of safety showed no unexpected adverse events. CONCLUSIONS: Although the overall short follow-up of the present study should be taken into account, lercanidipine is an effective and safe treatment option for BP control in adult patients with mild-to-moderate primary hypertension.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2014) conducted an RCT in Mild-to-moderate primary hypertension (n=281). Lercanidipine hydrochloride vs. Felodipine sustained-release tablets was evaluated on Mean seated diastolic blood pressure (BP) change from baseline to 6 weeks of treatment. Lercanidipine hydrochloride reduced diastolic blood pressure from 96 to 83 mmHg, with effects similar to felodipine sustained-release.
Synapse has enriched 10 related papers. Consider them for comparative context: